BioSpace News Archive

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors

Expansion will further affordable infusion access for patients with chronic diseases

Canopy Rivers Inc. is pleased to share that its portfolio company, James E. Wagner Cultivation Corporation, has received approval of a licence amendment from Health Canada.

Direct Biologics, LLC announces the launch of ExoFloTM Exosomes.

Takeda Pharmaceutical Company Limited, R&D-driven, global biopharmaceutical company with a leadership position in rare diseases, has announced updated results from its phase IIIb/IV clinical trial for ADYNOVATE® [Antihemophilic Factor, PEGylated] at the 27th Annual International Society on Thrombosis and Haemostasis Congress, in Melbourne, Australia.

Octapharma announced that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a scientific symposium at the 27th International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.

Interim results from verITI-8, an ongoing prospective, phase 4 study evaluating the efficacy of Elocta®, for first-time Immune Tolerance Induction for people with severe haemophilia A with inhibitors were presented.

Evidence indicating human herpesvirus 6 and related herpesviruses may contribute to the causation of Alzheimer’s disease was presented in late June in a day-long session of the 11th international HHV-6 conference, in Quebec City, reports Leslie Norins, MD, PhD, CEO of Alzheimer’s Germ Quest, Inc. who attended.

Horizon Discovery Group plc, announced that Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology.

inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets